MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1001/jamaoncol.2019.1568

Медицинская библиотека · JAMA oncology · 2019

Association of Immune Marker Changes With Progression of Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma.

Landgren Ola, Hofmann Jonathan N, McShane Charlene M, Santo Loredana, Hultcrantz Malin, Korde Neha, Mailankody Sham, Kazandjian Dickran, Murata Kazunori, Thoren Katie, Ramanathan Lakshmi, Dogan Ahmet, Rustad Even, Lu Sydney X, Akhlaghi Theresia, Kristinsson Sigurdur Y, Björkholm Magnus, Devlin Sean, Purdue Mark P, Pfeiffer Ruth M, Turesson Ingemar

СтатьяПеревод в очереди

Аннотация

IMPORTANCE

Multiple myeloma is consistently preceded by monoclonal gammopathy of undetermined significance (MGUS). Risk models that estimate the risk of progression from MGUS to multiple myeloma use data from a single time point, usually the initial workup.

OBJECTIVE

To longitudinally investigate the alterations of serum immune markers with stable vs progressive MGUS.

DESIGN, SETTING, AND

PARTICIPANTS

This prospective cross-sectional cohort study included 77 469 adult participants aged 55 to 74 years in the screening arm of the National Cancer Institute Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial who had a diagnosis of progressing MGUS (n = 187) or stable MGUS (n = 498), including light-chain subtype, from November 1993, through December 2011. For each participant, all available serially stored prediagnostic serum samples (N = 3266) were obtained. Data analysis was performed from April 2018, to December 2018.

MAIN OUTCOMES AND MEASURES: Serum protein and monoclonal immunoglobulin levels, serum free light chains, and serum light chains within each immunoglobulin class were measured.

RESULTS

Of 685 individuals included in the study, 461 (67.3%) were men; the mean (SD) age was 69.1 (5.6) years. In cross-sectional modeling, risk factors associated with progressive MGUS were IgA isotype (adjusted odds ratio [OR], 1.80; 95% CI, 1.03-3.13; P = .04), 15 g/L or more monoclonal spike (adjusted OR, 23.5; 95% CI, 8.9-61.9; P < .001), skewed (<0.1 or >10) serum free light chains ratio (adjusted OR, 46.4; 95% CI, 18.4-117.0; P < .001), and severe immunoparesis (≥2 suppressed uninvolved immunoglobulins) (adjusted OR, 19.1; 95% Cl, 7.5-48.3; P < .001). Risk factors associated with progressive light-chain MGUS were skewed serum free light chains ratio (adjusted OR, 44.0; 95% CI, 14.2-136.3; P < .001) and severe immunoparesis (adjusted OR, 48.6; 95% CI, 9.5-248.2; P < .001). In longitudinal analysis of participants with serial samples prior to progression, 23 of 43 participants (53%) had high-risk MGUS before progression; 16 of these 23 (70%) experienced conversion from low-risk or intermediate-risk MGUS within 5 years. Similar results were found for light-chain MGUS.

CONCLUSIONS AND RELEVANCE: The findings of evolving risk patterns support annual blood testing and risk assessment for patients with MGUS or light-chain MGUS.

Для цитирования: Landgren Ola, Hofmann Jonathan N, McShane Charlene M, Santo Loredana, Hultcrantz Malin, Korde Neha, Mailankody Sham, Kazandjian Dickran, Murata Kazunori, Thoren Katie, Ramanathan Lakshmi, Dogan Ahmet, Rustad Even, Lu Sydney X, Akhlaghi Theresia, Kristinsson Sigurdur Y, Björkholm Magnus, Devlin Sean, Purdue Mark P, Pfeiffer Ruth M, Turesson Ingemar. Association of Immune Marker Changes With Progression of Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma.. JAMA oncology. 2019. DOI: 10.1001/jamaoncol.2019.1568.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.